An external quality assessment survey of testing facilities in UK clinical laboratories for the detection of drugs of abuse was made with nine freeze-dried samples of urine containing representative drugs with their metabolites from the following seven classes; amphetamines and stimulants, barbiturates, cannabinoids, cocaine, minor tranquillisers, opiates and non-opiate narcotics. Reports were received from 120 laboratories. Thirty six per cent of laboratories reported on all seven drug classes and 71 % on the five classes excluding cannabinoids and cocaine. A single drug screening technique was used by 32 % of laboratories whilst 46 % were able to perform tests by both immunological and chromatographic techniques. There was a mean level of false positive reporting of 4·3 % and an observed level of false negative reports of 8'4%, the latter underestimating the true frequency. The minor tranquillisers, cocaine and benzoyl ecgonine were the most frequently missed analytes. Several false reports had important potential implications for patient care.
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Services in the United Kingdom for the clinical testing of urine for drugs of abuse have developed within existing hospital laboratory services in response to local demand. The 1984 guidelines of good clinical practice in the treatment of drug misuse issued by the then Department of Health and Social Security' indicated that the range of analyte groups for inclusion in a screening service should be the opioids, barbiturates, amphetamines, alcohol and minor tranquillisers.
Regulations for the accreditation of laboratories performing employment screening for drugs of abuse based on performance in external quality assessment schemes are being implemented in the USA. 2 In addition to specifying the analyte range, the detailed guidelines stipulate the threshold concentration that is to determine the presence or absence of each analyte. The accreditation programmes further require that both preliminary and quantitative confirmatory testing (by a technique based on a different chemical or physical principle to the preliminary technique) be performed at a single laboratory site. Performance requirements are rigorous, but when applied in recent American Association for Clinical Chemistry (AACC) surveys of subscribers to the AACC Toxicology Surveys Plus quality assessment program, a small subset of subscribers who were able to perform the necessary confirmatory tests were shown to produce an accuracy of> 95 %. 3.4 We report the results of an open quality assessment survey of clinical laboratories in the United Kingdom. The range and concentration of analytes selected were appropriate to clinical testing for drugs of abuse. In contrast to the AACC surveys, there was no preselection of laboratories as we wished to obtain data indicative of the range and quality of the testing services as operated. A similar non-selective survey has been reported from the first year of operation of the Spanish Proficiency testing programme.s
MATERIALS AND METHODS
Nine freeze-dried aliquots of 25 mL urine in rubber stoppered glass bottles were distributed in three batches in April and October 1987, and February 1988 to some 150 potential centres in the UK for the analysis of drugs of abuse identified from the responses to a questionnaire circulated by the Association of Clinical Biocnem-213 ists. The urine was heat treated at 60°C for It h before drying. The composition of the samples is summarised in Table 1 . An unsuccessful attempt was made to spike sample 3 with amylobarbitone and hydroxyamylobarbitone.
Concentrations of abused analytes both spiked and present as metabolites in the base urine were generally greater or equal to 1mg/L so as to be easily confirmable by two distinct analytical techniques. Exceptions are as detailed below. The total concentration of metabolites present in the base urine samples was assessed semi-quantitatively by thin-layer chromatography (TLC) and by Syva Emit assays (Syva, Palo Alto, USA). At the spiked concentration, cocaine, benzoyl ecgonine and the cannabis metabolite are below the threshold of some chromatographic assay techniques. All except the cannabinoid are easily detectable by immunological techniques. The concentration of cannabis metabolite in sample 3 was set at a high clinically relevant value but below the cut-off of certain immunological kits applied in cases of drug intoxication. The total concentration of pholcodine metabolites in sample 2 was greater than I mgJL but they were invisible by TLC in sample 8. The concentration in sample 8 was greater than the O' 3 mg/L cut-off of the non-specific immunoassays for opiates. The total concentration of benzodiazepine metabolites in sample 3 was also low but above the 0·3 mg/L cut-off of the Emit assay. Although detection thresholds suitable for clinical use have yet to be fully defined, we have taken the concentrations of all drugs present as metabolites in the base urine or as spiked compounds to be above desirable detection thresholds. In subsequent data analysis we categorize laboratory reports as being 'correct' or 'incorrect' on this basis, and references to 'false positive' and 'false negative' reports should be understood in this context.
A letter sent with the samples requested laboratories to analyse the samples as potential clinical drugs of abuse specimens. A data sheet was also provided onto which the laboratory was asked to encode their results. No guidance was given as to the range of analytes to be included as we wished to survey the current practice in the United Kingdom without implying a notional standard. The laboratory entered the name of the analyte, metabolite or group and specified the report they would make from the list; present, not found, uncertain, not reported and not tested. 'Not reported' was intended for use with analytes such as caffeine which may be detected in the urine samples at non-abuse concentrations. For each analyte or group reported, the data sheet requested information regarding the individual tests that had been performed in determining the overall report. Space was provided for up to three separate tests which were to be entered in the order used. For each test, the laboratory was asked to enter the technique used and the result from the range; positive, negative and uncertain. Where a technique such as TLC was used twice with different protocols, two separate entries were requested.
Statistical comparison of frequencies were made by the Chi-square test.
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RESULTS

Sample preparation
Two problems arose during sample preparation. First, concentrations of 1·7 mg/L amylobarbitone and 4·6 mgJL hydroxyamylobarbitone added to sample 3 were virtually undetectable after sample processing. This technical problem may have resulted from precipitation of the barbiturate on addition to the urine specimen and was successfully overcome in the formulation of sample 6.
The second problem was demonstrated by the occurrence of positive reports for amphetamine by both chromatographic and immunological tests in sample 9. Although particularly evident in sample 9, they were shown to be due to material also present in samples 7 and 8 and which was an artefact generated in the freezedrying processes, being absent from liquid material before drying. The contaminant can be shown not to be amphetamine by its failure to respond to the acetone-shift procedure in gasliquid chromatography (GC).6 Further studies by GC-mass spectrometry (R Caldwell, personal communication) have tentatively identified the interfering substance as N-ethylaniline derived from breakdown of a rubberiser present in the stoppers used in bottling this batch of three samples.' N-ethylaniline does not, however, cross-react in the Emit assay at the O' 5 rng/L concentration detected by GC in sample 9. Hence the nature of the observed interference with this immunological technique is unclear.
Laboratory classification
Between 92 and 103 replies were received for each of the nine survey samples from a total of 120 laboratories.
National Health Service laboratories made up 105 of this total. They ranged from wardside clinics, who performed testing of specific analytes to monitor patient compliance, to centres equipped to perform confirmatory testing on a full range of analytes. These latter centres included the Regional toxicology laboratories used by several of the survey participants to perform verification on clinical samples positive in their preliminary screens. The samples described in this study were not referred for verification. There were four academic departments, two armed forces laboratories, one public analyst, one probation service centre, one voluntary organisation and six commercial laboratories. The latter included manufacturers of kits used in drugs of abuse testing.
Techniques used
The analytical techniques reported as being used are summarised in Table 2 . Techniques applicable to a range of analytes fell into two broad groups; the chromatographic and the immunological.
The most widely used chromatographic technique was commercial TLC (Toxi-Iab, Mercia Diagnostics Ltd, Guildford, UK) whilst the Emit systems were the commonest of the immunological techniques. Other commercial immunoassay techniques were the Abbott TDx (Abbott Laboratories Ltd, Wokingham, UK) and the Perkin-Elmer (Perkin-Elmer Ltd, Beaconsfield, UK) polarisation fluoroimmunoassays, and radioimmunoassays (RIA) which included the DPC assays (Diagnostic Products (UK) Ltd, Abingdon, UK). In addition to these general purpose techniques, a number of techniques specific to a single analyte or analyte group were in use. They were the BCL opiates test (The Boehringer Corporation (London) Ltd, Lewes, UK) and several colour spot tests and enzymatic assays.
As described in the following section, a change in reporting practice occurred over the course of the survey, there being an increase in the number of analytes reported. This increase was mirrored by a significant (P < 0,001) change in the numbers of tests performed by the different techniques. Whereas the number of tests performed by Emit and BCL did not differ between the three sets of samples (P > 0'1), there were increased numbers of reports of tests by all chromatographic techniques, by RIA and by Abbott TDx.
The use of combinations of techniques was determined to identify the number of laboratories with the ability to confirm the presence of an analyte by use of a technique based on an alternative assay principle ( Analytes reported Analytes were reported by chemical name, less frequently by trade name and, in the case of metabolites, by reference to the parent compound. There was use of American nomenclature such as meperidine for pethidine and reference to compounds such as ethinamate not available in the United Kingdom. Both probably result from use of transatlantic documentation supplied with certain assay kits. Where reports were for the same chemical entity they were combined as were reports for the stereo-isomers ephedrine and pseudoephedrine, and quinine and quinidine. Reports for the proprietary mixture Diconal (Calmic Medical Division, Crewe, UK) were taken as separate reports for the two active ingredients (dipipanone and cyclizine). Following this standardisation of nomenclature, there was a total of 8277 reports for a total of 166 analytes in the nine survey samples. The majority of analytes or analyte groups were, however, mentioned by few participants, only 38 (23 %) being reported by more than 10 % of laboratories. A list of these analytes, excluding caffeine, nicotine, quinine and ethanol, appears in Fig. I. It was apparent from a comparison between data for the three sets of samples, that laboratories responded to the results of the early circulations of samples and altered their reporting in subsequent sets, generally increasing the range of analytes reported to match that given in the data analysis. The mean number of reports received from each laboratory increased over the three sets of samples from 8·6 to 9·8 and to 10·2. The changes were widely spread across laboratories and the abused analyte groups, though the increases were necessarily less for categories of drugs reported throughout with high frequency.
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Service offered A measure of the service offered was made by counting the number of laboratories who returned reports for at least one member of each of the seven major classes of drugs of abuse represented in the survey samples. Of the total of 120 laboratories, the number reporting on specific analyte groups were as follows; opiates 114, non-opiate narcotics 104, amphetamines and stimulants 113, barbiturates 104, cocaine or its metabolite 92, tranquillisers including the benzodiazepines 80, and cannabinoids 62. Fortythree laboratories covered the complete range of seven analyte groups. Sixty-six reported on all groups except cannabinoids, 85 if cocaine was also excluded and 96 on the narcotics, amphetamine and barbiturate groups. Several 'present' reports for the opiate and amphetamine groups were not accompanied by reports either identifying a specific analyte or excluding as 'not found' the key abused members of the group. Of the total of 271 'present' reports for opiates in the survey samples, 50 % were unconfirmed in one of these ways. Five per cent were from technique combinations that included a chromatographic test but 45 % were the result of immunological tests alone, 18 % being from the BCL opiate test. Fifty-three per cent of the 51 'present' reports for the amphetamines group were unconfirmed, 18 % were from techniques that included a chromatographic procedure whilst 35 % were from immunological or colour spot tests alone. The 15 reports of sympathomimetic amines 'present' were all confirmed by a report identifying a specific analyte.
Styles of reporting
The number of items reported by a laboratory for each sample showed a skewed distribution with a range from one to 99 analytes and a mode of seven. There were three styles of reporting. First were reports of a fixed range of compounds whether present or not. They originated from laboratories performing their assays by immunological tests alone who reported on a mean of six analytes and also from laboratories employing chromatographic techniques some of whom returned long and comprehensive lists of analytes. The other two styles of reporting were of variable lists of analytes the contents of which depended on the nature of the sample. One group of laboratories mentioned just those compounds detected as present in the sample though they had clearly screened for and excluded a wide range of compounds. The final group produced reports Of the 8277 reports received, a total of 547 were incorrect, 210 being false negative reports. The reporting errors were widely distributed between laboratories, 114 of the participants being involved during the survey as a whole. Analysis of the combinations of assay techniques used by laboratories when a reporting error resulted showed 75 % of false positive reports and 83 % of false negative reports to be from unconfirmed tests by a single technique. The use of confirmatory tests thus apparently failed to reduce the overall frequency of reporting errors, there being no significant difference (P > 0'05) in the ratio of confirmed to unconfirmed reports A survey of drugs of abuse testing 219 between those in error as compared with the remainder. There was, however, a significant difference (P < 0'01) in the relative frequency of techniques used in producing the unconfirmed reports that were in error, a higher than expected number of BeL opiate tests and fewer than expected Abbott TDx tests resulting in false reporting errors. When the confirmed tests resulting in errors were considered, the order of use of techniques was important. There was a small but significant excess (P < 0'05) of errors from technique combinations starting with an immunological technique. A summary of the false reports is presented in Table 3 for the seven analyte classes. Errors resulting from problems in sample preparation have been excluded from the table.
Reporting errors were greatest where samples presented a positive analytical challenge. Thus, errors for the amphetamines group emanated largely from samples 2 and 8 containing ephedrine and phenylpropanolamine. In sample 2, for example, 24 % of participants incorrectly identified these compounds as being either amphetamine or methyl-amphetamine. The pholcodine-containing samples proved difficult for laboratories attempting precise identification of the opiate concerned and the low level of codeine in sample 4 was frequently missed in the presence of morphine. For the critical analyte morphine, an average of 6·5 % of participants incorrectly reported morphine in samples that contained pholcodine or dihydrocodeine, whilst 5·9 % missed morphine concentrations of 1·5mg/L combined with 5 mg/L morphine-3glucuronide.
Inspection of the overall column lengths in Fig. 1 shows the higher level of reporting for specific compounds when they were present in the sample and conversely the reduced level of correct negative reporting. This reduction in the level of negative reporting is bound to cause some under-reporting of false negatives. Comparison of the observed level of reporting for analytes present in the sample (Table 3 ) with the number of potential reports implied by the number of laboratories providing a service for the analyte groups given in a previous section, shows the mean level of under-reporting of negative results to be 12·3 %. An attempt was made to estimate the proportion of these missing reports that would be in error by comparison of the analytes reported by each laboratory over the nine survey samples. Where a laboratory reported on an analyte or group in one sample, it was assumed that it would have screened for the analyte in other samples on which it reported. The data were then inspected where a predicted report was absent to eliminate those cases where a specific analyte had been given instead of a group report or vice versa. Reporting errors leading to missing values, cases with reports that indicated that further unidentified analytes had been detected and missing values from early samples that appeared to result from changes in reporting practice were also excluded. There remained 70 cases which could be interpreted as being candidates for missing false negative reports, a level of under-reporting of false negatives of25 %. A breakdown of these cases by analyte group is presented in the final column of Table 3 .
Comparison of techniques
The mean number of results by each method are displayed in an identical form to the report data in Fig. 1 for the chromatographic techniques and in Fig. 2 for the immunological techniques over the more limited range of analytes appropriate for these assays. Immunoassay results when used in combination with other technique data to identify analytes not characterised specifically by the immunoassay technique alone are reassigned in Fig. 2 to their appropriate analyte group with the correct result interpretation for the wider group.
Horizontal comparisons across the Figs can be used to locate the source of the reporting errors displayed in the first column of Fig. 1 . False negative tests for amphetamines and stimulants occurred mainly with the chromatographic techniques. Sixty-eight per cent of the false posi-tive amphetamine reports resulted from the artefact present in samples 7-9 and were based on positive tests by both chromatographic and Emit assays. The remaining false positive reports (Table 3) were split between laboratories basing their reports on tests by the TLC-kits and two Emit techniques.
False negative testing for barbiturates was worst by in-house TLC and by the miscellaneous methods including spot-tests not presented in the Figs. Cannabinoids, assayed in the main by the immunological techniques, were missed frequently by the Emit kits. Both cocaine and benzodiazepine containing samples were poorly handled by the TLC techniques. These analytes also feature strongly in the analysis for missing false negative reports, contributing 33 cases to the total. It must be reiterated, however, that in the case of cannabinoids, cocaine and benzodiazepines, concentrations present were below threshold for most chromatographic and for specific immunoassay techniques in some samples which were the source of the majority of the false negative tests.
Errors in the assay of opiates were varied. The TLC-kits method group was dominant in both false positive and false negative types of error though most techniques were represented. The higher than expected number of BCL errors has been noted above. No particular method group was dominant in the errors with the non-opiate narcotics.
DISCUSSION
The survey demonstrated considerable diversity in the nature of the sites and of the services available in the United Kingdom for the clinical testing for drugs of abuse in urine samples. Of the survey group, some 32 % used a single technique whilst 46 % were able to perform confirmatory tests by use of distinct immunological and chromatographic techniques. However, less than 30 % of 'present' reports were actually confirmed.
By purposely not supplying details of the analytes to be reported, we hoped to provide a base-line against which to judge future performance in United Kingdom laboratories. Our intervention with the survey had an immediate influence and caused an increase in the number of analytes reported by some 19 %. The data presented are thus an overstatement of the level of reporting prior to the survey. Despite this, it was clear that there existed general unanimity in the range of analytes that should be included in a clinical screening programme for drugs of abuse, and 36 % oflaboratories reported on all seven of the drug classes included in the survey samples. The analytes most frequently omitted were cannabinoids and cocaine with 71 % of participants reporting on the remaining five drug classes. The style of reporting was, however, varied and there was a potentially misleading lack of standardisation in the nomenclature of analytes. More disturbing was the accuracy of the data reported. It might be argued that, since 75 % of false positive reports were the result of unconfirmed tests which may be referred elsewhere for verification, the amount of false information given out on controlled substances will be less than that suggested by the observed level of false positive reports. However, any level offalse positive reporting is unacceptable, and referral for verification will do nothing to reduce false negative reporting. Although the open design of the survey precluded direct measurement of the full extent of false negative reporting, at least 8 % and possibly 11 % of 'not found' reports were in error. Particular difficulty was experienced in the detection of cocaine and its metabolites when spiked at abuse concentrations.
In summary, we have identified several areas of drugs of abuse testing that are in urgent need of appraisal. Foremost is a need for laboratories to define clear objectives before embarking on a testing programme. If the thresholds implied by our choice of analyte concentrations prove to be satisfactory for the clinical field, the observed level of false negative reporting demonstrates that provision of screening services based on present laboratory protocols will be unsatisfactory unless a proportion of missed positives can be tolerated, which is unlikely. Based on their specific objectives, a laboratory should be able to define both the repertoire of analytes to be tested and detection thresholds for each analyte. As well as methods suitable for these objectives, a considerable level of staff skill and experience is essential if the present false positive reports are to be eliminated. Unfortunately, even such apparently simple techniques as immunoassay need considerable care and understanding for accurate interpretation. Finally, workers in this field should seek to evolve standards of reporting which address issues such as the degree of data interpretation required. For example, should morphine present as a metabolite of codeine be reported? The samples described here formed the first in an ongoing quality assessment scheme for United Kingdom laboratories which will aim to facilitate the development of such standards and of the laboratory skills essential in this difficult field of analysis.
